Specialty Pharmacy

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the importance of collaboration during the pharmacy accreditation process.

Officials with the FDA have granted GBC0905, for the treatment of facioscapulohumeral muscular dystrophy (FSHD), an Orphan Drug Designation.

Patients with both private and public insurers face high denial rates across the United States for life-saving hepatitis C drugs, despite changes in restrictions and increased price competition.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape

A look at last week's top stories in the world of pharmacy.

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses data collection and analytics services that aggregators can offer manufacturers.

With the approval, rituximab has become the first biologic therapy approved by the FDA for PV, and the first major advancement in treatment of the condition in 6 decades.

Delayed or failed degree completion is associated with much higher economic consequences for advanced-degree as compared to baccalaureate-degree programs.

Indazole chloride may be able to reduce disability burden in patients with multiple sclerosis by producing good inflammation that promotes axon myelination.

Top news of the day from across the health care landscape

Among HIV-positive women with diabetes, HIV control has improved over time, but diabetes control has not.

An evaluation of the impact of persistence to oral antidiabetic medication on reducing the risk of hospitalization in adult patients with type 2 diabetes.

Although precision medicine holds promise for advanced cancer care, many oncologists indicated challenges in the adoption of new, targeted therapies.

Top news of the day from across the health care landscape.

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, goes into detail about how pharmacies can engage specialty-naive prescribers.

Emicizumab-kxwh is an antibody that activates the natural coagulation process in people with hemophilia A who lack factor VIII.

Upadacitinib is currently being tested in phase 3 trials of rheumatoid arthritis, psoriatic arthritis and Crohn’s disease, and is being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

Specialty pharmacies play a vital role in the patient journey from diagnosis to treatment.

Top news of the day from across the health care landscape.

Data revealed at ASCO shows combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel reduced the risk of death by 22% compared with bevacizumab and chemotherapy.

In a study presented at ASCO, Cemiplimab shows substantial activity and durable responses with an acceptable safety profile in treatment of metastatic cutaneous squamous cell carcinoma.

Pegfilgrastim-jmdb is the first biosimilar to pegfilgrastim (Neulasta) approved by the FDA.

Baricitinib is indicated as a monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs for adults with moderately-to-severely active rheumatoid arthritis.

American Society of Health-System Pharmacists board votes unanimously to create a new section of practitioners that will help members provide optimal patient care and medication therapy management in specialty pharmacy.

Top news of the day from across the health care landscape.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the importance of setting up organizations for success through effective education.

Medication nonadherence in the United States reportedly costs the health care system $300 billion annually, but is this figure accurate?

Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.

Durvalumab, an FDA-approved immunotherapy, met its second primary endpoint of overall survival in the phase 3 PACIFIC trial for stage 3 non-small cell lung cancer.